Skin Cancer

SKIN CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

COVID-19 Vaccination and Imaging Misinterpretation: An Interview With Lacey McIntosh, DO, MPH

Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
T-VEC Shows Promise as Neoadjuvant Therapy in Melanoma

Investigators compared recurrence-free survival and overall survival outcomes in patients randomly assigned to receive neoadjuvant talimogene laherparepvec (T-VEC) followed by immediate surgery or surgery alone.
A Statistical Fallacy Might Mar Study Findings on Bevacizumab in Melanoma

“‘Trended strongly’ is code for ‘we failed to meet statistical significance,’” remarked one expert, when she was asked to scrutinize the conclusions of a recent post hoc analysis.
Effects of Drugs Targeting Mitochondrial Respiration in Melanoma

Despite relying on glycolysis, there is growing evidence that many tumor types still have high levels of mitochondrial energy metabolism and functioning oxidative phosphorylation. One such subset of tumors is melanoma, potentially playing a role in both tumor progression and resistance to therapy. This has led researchers to wonder whether targeting mitochondrial respiration could be…
Research Shows Long-Term Benefit for Adjuvant Targeted Therapies in High-Risk Melanoma

More than half of patients with resected stage 3 melanoma with BRAF V600E or V600K mutations receiving a year’s worth of adjuvant dabrafenib and trametinib were still alive 5 years later.

VIDEO SERIES

Recent Advances in Melanoma Therapy

Targeted Treatments and Immunotherapies for Melanoma

Tailoring Treatments in Melanoma

Drug Resistance in Melanoma

Affordability of Melanoma Care

Melanoma: Treatment-induced Toxicity

Immunotherapy: A Decade of Improvements in Melanoma

Should Patients With Melanoma Receive Targeted Therapy or Immunotherapy First?

Melanoma: Checkpoints in the Pipeline

Targeting Therapy for Melanoma Subtypes

Melanoma: Targetable Genes in the Pipeline

Clinical Trials in Melanoma

SKIN CANCER NEWS

The combination may be an attractive option for some, but further research is needed to target the t

Risk for Cutaneous Squamous Cell Carcinoma Increases With Age

April 15, 2021

Pilocytic astrocytoma is a slow growing, relatively well-defined tumor that develops in the cerebrum, optic nerve pathways, brain stem, and cerebellum. It occurs most often in children and teens.2

Past Decade Has Seen Improved Outcomes in Melanoma Brain Metastasis

April 7, 2021

Circulating tumor DNA conveyed prognosis among patients with high-risk stage III melanoma, reinforcing the need to include this measure in clinical trial design.

Blood Cell Score for Identifying Aggressive Melanoma

March 30, 2021

Photomicrograph of a lymph node showing malignant melanoma.

Patterns in the Development of Melanoma Across Body Sites

March 24, 2021

As post-transplant medications are used to reduce the body’s immune reaction to a foreign organ, the

Increased Risk of Skin Cancer Linked to Long-Term Use of Certain Diuretics

March 19, 2021

Next post in Skin Cancer

Pilocytic astrocytoma is a slow growing, relatively well-defined tumor that develops in the cerebrum, optic nerve pathways, brain stem, and cerebellum. It occurs most often in children and teens.2

Past Decade Has Seen Improved Outcomes in Melanoma Brain Metastasis